Learn about the latest advances in inflammatory bowel disease (IBD) and advanced endoscopic procedures from the experts of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai. Ever since Mount Sinai physician Burrill Crohn, MD, and colleagues described the condition now known as Crohn’s disease, Mount Sinai gastroenterologists have been on the cutting edge of diagnosing and treating IBD and other gastrointestinal disorders. Bruce Sands, MD, MS is the Chief of the Division of Gastroenterology and Director of the Digestive Disease Institute. A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. Our Susan and Leonard Feinstein IBD Clinical Center, led by Jean-Frederic Colombel, MD, and Marla Dubinsky, MD, is at the forefront of research into the causes of IBD and leads the field in clinical trials that have advanced patient care. Additionally, at our Center for Advanced Colonoscopy and Therapeutic Endoscopy at Sinai (CACTES), led by Christopher DiMaio, MD, our physicians are pioneering new tools and techniques to identify, diagnose, and treat the most complex digestive disorders.
Referring a patient is easy. Just click the “Refer a Patient Online” button.
Latest Videos| View More >
See what makes our Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center unique.
An advanced radiotherapy technique called radiation segmentectomy may be effective against very early to early-stage hepatocellular carcinoma (HCC), a type of liver cancer that cannot be treated surgically or thermally.
This presentation highlights the epidemiology and current management of cholangiocarcinoma, as well as future therapeutic approaches
Dr. J. Antonio Quiros discusses the Pediatric Therapeutic Endoscopy Program at Mount Sinai
Joanne Lai, MD, discusses the range of pediatric gastroenterology services offered at Mount Sinai Doctors-Long Island.
Listen as David Dunkin, MD, discusses the advanced and innovative pediatric gastroenterology care provided at Mount Sinai Doctors-Brooklyn Heights
Case Based Question & Answer Session on Liver Pathology, Abnormal LFTs and Jaundice, Hepatitis B, Hepatitis C, Autoimmune Hepatitis, Alcoholic and Nonalcoholic Liver Disease, Cholestatic Liver Disease, Liver Tumors, Cirrhosis, Portal Hypertension ...
The founders of Trellus Health, LLC, discuss their resiliency-driven approach to inflammatory bowel disease treatment utilizing digital tools, care coordination, and support
COVID-19: Implications on Inflammatory Bowel Disease
Advances in FMT
Colon cancer screening: what to look for
Helping patients with pancreatitis
Managing Crohn's disease
Personalizing IBD treatment
Understanding IBD and the microbiome
Helping patients with IBD
Advances in Barrett's Esophagus
African Americans experience low rates of colorectal cancer screening
The Future of IBD treatment
Collaboration—among specialists in different disciplines, and between clinicians and bench scientists—is a hallmark of the Mount Sinai Health System and our Dr. Henry D. Janowitz Division of Gastroenterology. That approach is spotlighted ...
Gastroenterology and Mount Sinai Heart are among the specialties recognized at The Mount Sinai Hospital in Newsweek’s “The World’s Best Specialized Hospitals 2021.”
COVID-19 Vaccines for IBD Patients: International Consensus
The Icahn School of Medicine at Mount Sinai was ranked No. 3 in the world in U.S. News & World Report “Best University for Gastroenterology and Hepatology.” The Seventh Annual U.S. News & World Report “Best Global Universities” rankings ...
Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program
In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures.
Ustekinumab is more effective than placebo as an induction and maintenance therapy for UC.
New research in the disruptions in the GI tract of HIV-1 patients
Population analysis on IBD in Western Countries
Study of infants born to mothers with IBD
The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai is the only center in the country that is currently using ultrasound to monitor inflammation in inflammatory bowel disease patients.
A collaborative model between Gastroenterology and Rheumatology in the Department of Medicine at Mount Sinai is providing patients with IBD and arthritis a level of care few clinics in the world can offer, and researchers with a springboard ...
Mount Sinai Health System, which pioneered and continues to refine the technique of J-pouch surgery, has now created a Comprehensive Pouch Program to closely monitor patients after surgery, ensuring continuous, hands-on care designed to ...
Mount Sinai’s interventional endoscopy team continues to lead the field in innovation with the recent introduction of two novel procedures that are dramatically advancing treatment for patients with achalasia, necrotizing pancreatitis, ...
Two new Mount Sinai studies have defined novel approaches for treating Crohn’s disease and ulcerative colitis (UC).
The Mount Sinai Division of Liver Diseases has built on its nationally recognized expertise in fibrosis and fibrotic pathways to create the NASH Center of Excellence, concentrating under one umbrella a rich diversity of clinical and research ...
While gastroenterology is historically a male-dominated field, the ranks of female professionals are growing.
Intestinal ultrasound to monitor ulcerative colitis and Crohn's disease has become the standard of care in Canada and many parts of Europe, but has never gained a foothold in the United States.
A research database known as SECURE-IBD provides a quick and robust source of information to clinicians around the world about the use of IBD therapies like corticosteroids and the widely prescribed tumor necrosis factor (TNF) antagonists ...
SARS-CoV-2 has a spike protein that tethers itself to angiotensin converting enzyme 2 (ACE2) to gain entry to cells, and the intestinal tract has the highest expression of ACE2 in the body—even higher than in the lungs.
Researchers used whole-genome sequencing to identify 42 species of fecal microbiota that were especially likely to engraft successfully.
We launched a database called SECURE-IBD that has already yielded the insight that TNF antagonists appear to be a low-risk IBD therapy where COVID-19 is concerned, and another study, called ICARUS, intended to explore the seroprevalence ...